Novel and simple prognostic index for nasal natural killer/T-cell lymphoma

Background Few studies have investigated the prognostic factors for nasal natural killer (NK)/T‐cell lymphoma. Methods This was a retrospective multicenter clinical study. The clinical records of 36 patients with nasal NK/T‐cell lymphoma who had been first treated between 1996 and 2011 were collecte...

Full description

Saved in:
Bibliographic Details
Published inHead & neck Vol. 36; no. 4; pp. 551 - 556
Main Authors Hanakawa, Hiroyuki, Orita, Yorihisa, Sato, Yasuharu, Takao, Soshi, Marunaka, Hidenori, Morishita, Tokiwa, Yamashita, Yasuhiko, Hori, Yasutaka, Domae, Shuhei, Inokuchi, Ikuo, Akagi, Seiko, Kondo, Eisei, Iwaki, Noriko, Motomiya, Kana, Okumura, Hirokazu, Yoshino, Tadashi, Nishizaki, Kazunori
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.04.2014
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Few studies have investigated the prognostic factors for nasal natural killer (NK)/T‐cell lymphoma. Methods This was a retrospective multicenter clinical study. The clinical records of 36 patients with nasal NK/T‐cell lymphoma who had been first treated between 1996 and 2011 were collected from 12 hospitals. Results High serum levels of C‐reactive protein (≥1.0 mg/dL), lactate dehydrogenase (≥350 IU/L), and soluble interleukin‐2 receptor (sIL‐2R; ≥600 U/mL) were associated with worse prognosis. A prognostic score was devised by totaling the number of these 3 predictors: 0 or 1 = score 0; and 2 or 3 = score 1. As for tumor invasion, local invasion beyond the nasal cavity was associated with poor prognosis, and a prognostic score was devised as: tumor restricted to nasal cavity, yes = score 0; no = score 1. A novel prognostic index (NPI) was established based on these scores from 0 to 2. Disease‐specific survival rates at 5 years were: 90.0% for NPI = 0; 29.3% for NPI = 1; and 0.0% for NPI = 2. Conclusion Our NPI is valid for anticipating prognosis of nasal NK/T‐cell lymphoma. © 2013 Wiley Periodicals, Inc. Head Neck 36: 551–556, 2014
Bibliography:istex:274DF40D435368D506DA0FC4A461A1DF29095F71
ark:/67375/WNG-TK9LCPNW-5
ArticleID:HED23322
This work was presented at the 113th annual meeting of the Japan Otolaryngological Society, Niigata, Japan, May 9–12, 2012.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.23322